SEMA7A and ductal breast carcinoma in situ: To test our hypothesis that SEMA7A plays a role in progression of DCIS in patients, we examined SEMA7A expression in Early Stage Breast Tumors (SCAN-B) for breast cancers by biopsy type and found that SEMA7A mRNA is upregulated in invasive carcinomas compared to in situ carcinomas (Supp Fig. 1A).